A historic breakthrough in pancreatic cancer treatment! The FDA approves RevMed, a targeted therapy, with projected sales exceeding $9 billion by 2032.
Revolution Medicines (RevMed)'s new pancreatic cancer drug daraxonrasib has been approved for marketing by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy against the key molecular pathogenic mechanism of the disease, marking one of the most important breakthroughs in the field of pancreatic